David K. Lee, CEO of Servier Pharmaceuticals, shared a post by Servier Pharmaceuticals on LinkedIn, adding:
“Today feels like a meaningful moment to pause and reflect.
With Day One Biopharmaceuticals joining Servier US, we take an important step forward in our ability to serve patients living with rare cancers, including pediatric low grade glioma.
I have deep respect for what the Day One team has built, strong scientific, clinical, and commercial capabilities grounded in urgency for patients.
Together with Servier US, this combination strengthens our focus on delivering innovation with purpose and responsibility.
I am grateful to the teams who made this milestone possible and energized by what we can build together for patients and families.
Quotting Servier Pharmaceuticals‘s post:
“Today, we are pleased to welcome Day One Biopharmaceuticals to Servier.
Together, we strengthen our shared ambition to advance innovative treatments for children and adults living with rare cancers, starting with pediatric low-grade glioma.
By bringing together Servier US and Day One Biopharmaceuticals, we unite complementary scientific, clinical, and commercial strengths to continue to advance innovative oncology medicines for patients and families.
We look forward to what we will build together.”
Other articles featuring David K. Lee on OncoDaily.